Center for Scientific Review; Notice of Closed Meetings, 51637-51638 [2017-24143]
Download as PDF
<![CDATA[
Federal Register / Vol. 82, No. 214 / Tuesday, November 7, 2017 / Notices
include patients with clinical or
laboratory evidence of chronic hepatitis
C disease, such as the presence of
fibrosis by biopsy or noninvasive tests.
• Additional details on DAA drug
development in patients with
decompensated cirrhosis, including
recommendations for a review by an
independent adjudication committee for
all serious hepatic events, deaths, liver
transplantations, and changes in
prespecified alanine transaminase,
aspartate transaminase, and bilirubin
parameters and a recommendation for
long-term followup to characterize
clinical outcomes such as progression or
regression of liver disease, liver-related
mortality, occurrence of hepatocellular
carcinoma, or liver failure requiring
liver transplantation.
• Additional clarification on efficacy
endpoints, specifically additional posttreatment followup (e.g., 1 year or
longer) may be needed if one or more
drugs in the regimen has a long plasma
or intracellular half-life or prolonged
antiviral activity.
This guidance is being issued
consistent with FDA’s good guidance
practices regulation (21 CFR 10.115).
The guidance represents the current
thinking of FDA on ‘‘Chronic Hepatitis
C Virus Infection: Developing DirectActing Antiviral Drugs for Treatment.’’
It does not establish any rights for any
person and is not binding on FDA or the
public. You can use an alternative
approach if it satisfies the requirements
of the applicable statutes and
regulations. This guidance is not subject
to Executive Order 12866.
II. The Paperwork Reduction Act of
1995
This guidance refers to previously
approved collections of information that
are subject to review by the Office of
Management and Budget (OMB) under
the Paperwork Reduction Act of 1995
(44 U.S.C. 3501–3520). The collections
of information in 21 CFR parts 312 and
314 have been approved under OMB
control numbers 0910–0014 and 0910–
0001, respectively.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood
Institute; Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following Heart, Lung, & Blood Program
Project Review Committee meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Heart, Lung, and
Blood Initial Review Group; Heart, Lung, and
Blood Program Project Review Committee.
Date: December 1, 2017.
Time: 8:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Sheraton BWI (Baltimore), 1100 Old
Elkridge Landing Road, Baltimore, MD
21090.
Contact Person: Jeffrey H. Hurst, Ph.D.,
Scientific Review Officer, Office of Scientific
Review/DERA, National Heart, Lung, and
Blood Institute, National Institutes of Health,
6701 Rockledge Drive, Room 7208, Bethesda,
MD 20892, 301–435–0303, hurstj@
nhlbi.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)
Dated: November 1, 2017.
Michelle Trout,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–24144 Filed 11–6–17; 8:45 am]
BILLING CODE 4140–01–P
ethrower on DSK3G9T082PROD with NOTICES
III. Electronic Access
Persons with access to the internet
may obtain the guidance at either
https://www.fda.gov/Drugs/Guidance
ComplianceRegulatoryInformation/
Guidances/default.htm or https://
www.regulations.gov.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Dated: November 2, 2017.
Anna K. Abram,
Deputy Commissioner for Policy, Planning,
Legislation, and Analysis.
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
[FR Doc. 2017–24195 Filed 11–6–17; 8:45 am]
BILLING CODE 4164–01–P
VerDate Sep<11>2014
17:29 Nov 06, 2017
Jkt 244001
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
PO 00000
Frm 00041
Fmt 4703
Sfmt 4703
51637
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR Panel:
Synthetic Psychoactive Drugs and Strategic
Approaches to Counteract their Deleterious
Effects.
Date: November 30, 2017.
Time: 1:00 p.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Jasenka Borzan, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4214,
MSC 7814, Bethesda, MD 20892–7814, 301–
435–1787, borzanj@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Neuroimmunology,
Neuroinflammation and Brain Tumor.
Date: December 6, 2017.
Time: 10:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Nataliya Gordiyenko,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5202,
MSC 7846, Bethesda, MD 20892, 301–435–
1265, gordiyenkon@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Retinal Synapses and Circuitry.
Date: December 6, 2017.
Time: 12:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Afia Sultana, Ph.D.,
Scientific Review Officer, National Institutes
of Health, Center for Scientific Review, 6701
Rockledge Drive, Room 4189, Bethesda, MD
20892, (301) 827–7083, sultanaa@
mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
E:\FR\FM\07NON1.SGM
07NON1
51638
Federal Register / Vol. 82, No. 214 / Tuesday, November 7, 2017 / Notices
Dated: November 1, 2017.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–24143 Filed 11–6–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HOUSING AND
URBAN DEVELOPMENT
[Docket No. FR–6045–N–01]
Annual Indexing of Basic Statutory
Mortgage Limits for Multifamily
Housing Programs
Office of the Assistant
Secretary for Housing—Federal Housing
Commissioner, HUD.
ACTION: Notice.
AGENCY:
In accordance with Section
206A of the National Housing Act, HUD
has adjusted the Basic Statutory
Mortgage Limits for Multifamily
Housing Programs for Calendar Year
2017.
SUMMARY:
DATES:
January 1, 2017.
FOR FURTHER INFORMATION CONTACT:
ethrower on DSK3G9T082PROD with NOTICES
Daniel J. Sullivan, Deputy Director,
Office of Multifamily Development,
Department of Housing and Urban
Development, 451 Seventh Street SW.,
Washington, DC 20410–8000, telephone
(202) 402–6130 (this is not a toll-free
number). Hearing or speech-impaired
individuals may access this number
through TTY by calling the toll-free
Federal Information Relay Service at
(800) 877–8339.
SUPPLEMENTARY INFORMATION: The FHA
Down Payment Simplification Act of
2002 (Pub. L. 107–326, approved
December 4, 2002) amended the
National Housing Act by adding a new
Section 206A (12 U.S.C. 1712a). Under
Section 206A, the following are affected:
I. Section 207(c)(3)(A) (12 U.S.C.
1713(c)(3)(A));
II. Section 213(b)(2)(A) (12 U.S.C.
1715e(b)(2)(A));
III. Section 220(d)(3)(B)(iii)(I) (12 U.S.C.
1715k(d)(3)(B)(iii)(I));
IV. Section 221(d)(4)(ii)(I) (12 U.S.C.
1715l(d)(4)(ii)(I));
V. Section 231(c)(2)(A) (12 U.S.C.
1715v(c)(2)(A)); and
VI. Section 234(e)(3)(A) (12 U.S.C.
1715y(e)(3)(A)).
The Dollar Amounts in these sections
are the base per unit statutory limits for
FHA’s multifamily mortgage programs
collectively referred to as the ‘Dollar
Amounts.’ They are adjusted annually
(commencing in 2004) on the effective
date of the Consumer Financial
Protection Bureau’s adjustment of the
VerDate Sep<11>2014
17:29 Nov 06, 2017
Jkt 244001
$400 figure in the Home Ownership and
Equity Protection Act of 1994 (HOEPA)
(Pub. L. 103–325, approved September
23, 1994). The adjustment of the Dollar
Amounts shall be calculated using the
percentage change in the Consumer
Price Index for All Urban Consumers
(CPI–U) as applied by the Bureau of
Consumer Financial Protection for
purposes of the above-described HOEPA
adjustment.
HUD has been notified of the
percentage change in the CPI–U used for
the HOEPA adjustment and the effective
date of the HOEPA adjustment. The
percentage change in the CPI–U is 2.1
percent and the effective date of the
HOEPA adjustment is January 1, 2017.
The Dollar Amounts have been adjusted
correspondingly and have an effective
date of January 1, 2017.
These revised statutory limits, high
cost areas and per unit cost thresholds
for substantial rehabilitation may be
applied to FHA multifamily mortgage
insurance applications submitted or
amended on or after July 1, 2017, so
long as the loan has not been initially
endorsed.
The adjusted Dollar Amounts for
Calendar Year 2017 are shown below:
Basic Statutory Mortgage Limits for
Calendar Year 2017
Multifamily Loan Program
Section 207—Multifamily Housing
Section 207 pursuant to Section 223(f)—
Purchase or Refinance Housing
Section 220—Housing in Urban
Renewal Areas
Bedrooms
0 ................
1 ................
2 ................
3 ................
4+ ..............
Non-elevator
$51,575
57,133
68,244
84,116
95,228
0 ................
1 ................
2 ................
3 ................
4+ ..............
Non-elevator
$55,894
64,447
77,725
99,489
110,837
Bedrooms
0 ................
1 ................
2 ................
3 ................
4+ ..............
Non-elevator
$51,328
58,266
70,429
88,400
99,890
Elevator
$55,445
63,562
77,291
99,988
109,758
Section 231—Housing for the Elderly
Bedrooms
0 ................
1 ................
2 ................
3 ................
4+ ..............
Non-elevator
$48,800
54,555
65,147
78,401
92,173
Elevator
$55,445
63,562
77,291
99,988
109,758
Section 207—Manufactured Home Parks
Per Space—$23,678
Per Unit Limit for Substantial
Rehabilitation for Calendar Year 2017
The 2016 Multifamily Accelerated
Processing (MAP) Guide established a
base amount of $15,000 per unit to
define substantial rehabilitation for FHA
insured loan programs. Section 5.1.D.2
of the MAP guide requires that this base
amount be adjusted periodically based
on the percentage change published by
the Consumer Financial Protection
Bureau or other inflation cost index
published by HUD. Accordingly, the
2017 base amount per dwelling unit to
determine substantial rehabilitation for
FHA insured loan programs is $15,315.
Environmental Impact
Elevator
$60,158
66,657
81,734
102,368
115,749
Section 213—Cooperatives
Bedrooms
Section 221(d)(4)—Moderate Income
Housing
Elevator
$59,515
67,428
81,993
106,073
116,438
This issuance establishes mortgage
and cost limits that do not constitute a
development decision affecting the
physical condition of specific project
areas or building sites. Accordingly,
under 24 CFR 50.19(c)(6), this notice is
categorically excluded from
environmental review under the
National Environmental Policy Act of
1969 (42 U.S.C. 4321).
Dated: October 31, 2017.
Dana T. Wade,
General Deputy Assistant Secretary for
Housing.
[FR Doc. 2017–24171 Filed 11–6–17; 8:45 am]
Section 234—Condominium Housing
Bedrooms
0 ................
1 ................
2 ................
3 ................
4+ ..............
PO 00000
Frm 00042
Non-elevator
$57,035
65,762
79,311
101,521
113,098
Fmt 4703
Sfmt 9990
BILLING CODE 4210–67–P
Elevator
$60,021
68,806
83,667
108,239
118,812
E:\FR\FM\07NON1.SGM
07NON1
]]>Agencies
[Federal Register Volume 82, Number 214 (Tuesday, November 7, 2017)]
[Notices]
[Pages 51637-51638]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-24143]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Center for Scientific Review Special Emphasis
Panel; PAR Panel: Synthetic Psychoactive Drugs and Strategic
Approaches to Counteract their Deleterious Effects.
Date: November 30, 2017.
Time: 1:00 p.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Jasenka Borzan, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4214, MSC 7814, Bethesda, MD
20892-7814, 301-435-1787, borzanj@csr.nih.gov.
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Member Conflict: Neuroimmunology, Neuroinflammation and Brain
Tumor.
Date: December 6, 2017.
Time: 10:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892 (Telephone Conference Call).
Contact Person: Nataliya Gordiyenko, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5202, MSC 7846, Bethesda, MD
20892, 301-435-1265, gordiyenkon@csr.nih.gov.
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Member Conflict: Retinal Synapses and Circuitry.
Date: December 6, 2017.
Time: 12:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892 (Telephone Conference Call).
Contact Person: Afia Sultana, Ph.D., Scientific Review Officer,
National Institutes of Health, Center for Scientific Review, 6701
Rockledge Drive, Room 4189, Bethesda, MD 20892, (301) 827-7083,
sultanaa@mail.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.306,
Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893,
National Institutes of Health, HHS)
[[Page 51638]]
Dated: November 1, 2017.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2017-24143 Filed 11-6-17; 8:45 am]
BILLING CODE 4140-01-P
